Antibacterial Therapy: Effect on Healing and Relapse of Peptic Ulcer Disease

  • G. Börsch

Abstract

Helicobacter pylori (formerly Campylobacter pylori, H. pylori, HP) is rapidly evolving as the single most important factor in the pathogenesis of ulcer disease, at least gastritis-associated duodenal ulcer disease [13]. Unlike the underlying genetic predispositions of this condition, H. pylori has the tremendous practical advantage of being a treatable condition.

Keywords

Prostaglandin Bismuth Tetracycline Cimetidine Gastritis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bayerdörffer E, Ottenjann R (1988) The role of antibiotics in Campylobacter pylori associated peptic ulcer disease. Scand J Gastroenterol [Suppl 142] 23:93–100.CrossRefGoogle Scholar
  2. 2.
    Bayerdörffer E, Kasper G, Pirlet T, Sommer A, Ottenjann R (1987) Ofloxacin in der Therapie Campylobacter-pylori-positiver ulcera duodeni. Dtsch Med Wochenschr 112:1407–1411.PubMedCrossRefGoogle Scholar
  3. 3.
    Bayerdörffer E, Pirlet T, Sommer A, Kasper G, Ottenjann R (1988) Ofloxacin in der Therapie “resistenter” Ulcera duodeni. Z Gastroenterol 26:155–159.PubMedGoogle Scholar
  4. 4.
    Bianci Porro G, Lazzaroni M (1988) Campylobacter pylori and ulcer recurrence. Lancet 1:593.CrossRefGoogle Scholar
  5. 5.
    Bianci Porro G, Lazzaroni M (1989) Campylobacter pylori and peptic ulcer therapy. Gastroenterol Clin Biol 13:107 B–111 B.Google Scholar
  6. 6.
    Borody T, Cole P, Noonan S, Morgan A, Ossip G, Maysay J, Brandi S (1988) Long-term Campylobacter recurrence post eradication. Gastroenterology 94:A 43.Google Scholar
  7. 7.
    Börsch G (1987) Campylobacter pylori: new and renewed insights into gastritis-associated ulcer disease (GAUD). Hepatogastroenterology 34:191–193.PubMedGoogle Scholar
  8. 8.
    Börsch G (1989) Ist Campylobacter pylori der Erreger der Ulkuskrankheit? Pro. Z Gastroenterol 27:121–126.PubMedGoogle Scholar
  9. 9.
    Börsch G, Wegener M, Reitemeyer E, Mai U, Opferkuch W (1989) Clinical results and medium term follow-up studies after eradication of Campylobacter pylori. In: Mégraud F, Lamouliatte H (eds) Gastroduodenal pathology and Campylobacter pylori. Elsevier, Amsterdam, p 599.Google Scholar
  10. 10.
    Coghlan JG, Gilligan D, Humphreys H, McKenna D, Dooley C, Sweeney E, Keane C, O’Morain C (1987) Campylobacter pylori and recurrence of duodenal ulcers — a 12-month followup study. Lancet II: 1109–1111.CrossRefGoogle Scholar
  11. 11.
    Coghlan JG, Tobin A, O’Morain C (1989) Campylobacter pylori and ulcer treatment. In: Rathbone BJ, Heatley RV (eds) Campylobacter pylori and gastroduodenal disease. Blackwell, Oxford, p 232.Google Scholar
  12. 12.
    Eberhardt R, Kasper G, Dettmer A, Höchter W, Hagena D (1988) Wirkung von Wismutsubsalicylat versus Cimetidin auf Campylobacter pylori, Ulkusheilung und-rezidivrate. Med Klin 83:402–405.Google Scholar
  13. 13.
    Graham DY (1989) Campylobacter pylori as a pathogenic factor in duodenal ulcer: the case for. Scand J Gastroenterol [Suppl 160] 24:46–52.CrossRefGoogle Scholar
  14. 14.
    Graham DY (1989) Campylobacter pylori and peptic ulcer disease. Gastroenterology 96:615–625.PubMedGoogle Scholar
  15. 15.
    Graham DY, Lew GM, Michaletz PA (1989) Randomized controlled trial of the effect of eradication of C. pylori on ulcer healing and relapse. Gastroenterology 96: A 181.Google Scholar
  16. 16.
    Humphreys H, Bourke S, Dooley C, McKenna D, Power B, Keane CT, Sweeney EC, O’Morain C (1988) Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial. Gut 29:279–283.PubMedCrossRefGoogle Scholar
  17. 17.
    Lambert JR, Borromeo M, Korman MG, Hansky J, Eaves ER (1987) Effect of colloidal bismuth (De-Nol) on healing and relapse of duodenal ulcers — role of Campylobacter pyloridis. Gastroenterology 92:1489.Google Scholar
  18. 18.
    Marshall BJ (1989) Antimicrobial therapy of duodenal ulcer? Hold off for now. Reply. Gastroenterology 97:510.Google Scholar
  19. 19.
    Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, Phillips M, Waters TE, Sanderson CR (1988) Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet II:1437–1442.CrossRefGoogle Scholar
  20. 20.
    Smith AC, Price AB, Borriello P, Levi AJ (1988) A comparison of ranitidine and tripotassium dicitrato-bismuth (T.D.B.) in relapse rates of duodenal ulcer. The role of Campylobacter pylori (C.P.) Gastroenterology 94:A431.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • G. Börsch
    • 1
  1. 1.Department of Medicine, Elisabeth-HospitalAcademic Teaching Hospital of the University of Essen Medical SchoolEssenGermany

Personalised recommendations